Previsión
El precio objetivo medio de los analistas es de 60,88 € (+143,52 %). La mediana es de 56,96 € (+127,84 %).
| Comprar |
18 |
| Mantener |
2 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Celldex puts Barzolvolimab in the spotlight – pivotal Phase‑III data expected by end of 2026
At the Cantor conference, Celldex presented Barzolvolimab as its lead candidate for chronic spontaneous urticaria (CSU), highlighting strong Phase‑II results (65% angioedema‑free patients vs. 25% for placebo) and a large Phase‑III program enrolling nearly 2,000 patients. CSU data are expected by the end of 2026; the readout will determine commercial prospects and whether other projects such as CDX‑622 and atopic dermatitis studies will continue. Management emphasized a consistent safety profile in about 700 patients treated so far and the potential for a premium‑pricing strategy based on durable efficacy; no financial figures were disclosed. » Más en de.investing.com
Celldex Therapeutics reaches 52-week high at $40.30
Celldex Therapeutics’ stock rose to a 52-week high of $40.30, giving it a market capitalization of about $3.16 billion; the share has gained 73% over six months and 86.85% year to date. InvestingPro currently rates the stock as overvalued versus its fair value. At the same time, Celldex has discontinued the Phase II study of barzolvolimab in prurigo nodularis after failing to meet the primary and key secondary endpoints, prompting differing analyst price targets (Canaccord slightly lowered, Guggenheim raised, UBS reiterated). Chief Financial Officer Sam Martin announced he will retire in March 2027. » Más en de.investing.com
Celldex shares fall after failed phase‑2 trial of barzolvolimab
Celldex reported that the phase‑2 trial of barzolvolimab in prurigo nodularis did not meet the primary and key secondary endpoints, sending the stock sharply lower in after‑hours trading. Barzolvolimab markedly reduced mast cells and serum tryptase but showed no significant improvement in itch or skin lesions versus placebo. Celldex is discontinuing the prurigo nodularis study, emphasizes a favorable safety profile, and will continue developing barzolvolimab in other indications; Phase‑3 topline data for chronic spontaneous urticaria are expected in Sep/Oct 2026. » Más en de.investing.com
Celldex Therapeutics hits 52-week high at $39.16
Shares of Celldex Therapeutics climbed to a new 52-week high of $39.16, having nearly doubled from a low of $19.72 and bringing market capitalization to about $3.07 billion. Investor confidence is supported by positive clinical data, including promising Phase 1 results for CDX-622 and continued improvements with barzolvolimab in angioedema. Several analysts raised their valuations or maintained buy ratings (UBS: Buy; Wells Fargo: Overweight with a $54 target; Barclays: upgraded to Overweight), while InvestingPro rates the stock as overvalued relative to its fair value. » Más en de.investing.com
Celldex Therapeutics posts durable Phase 2 barzolvolimab data, supports potential 2027 CSU approval
Celldex reported updated Phase 2 findings showing barzolvolimab produced rapid, sustained improvements in angioedema and chronic spontaneous urticaria symptoms, with benefits evident seven months after dosing. UBS raised its price target and kept a Buy rating, citing a favorable Phase 3 outlook that could enable approval in 2027. The data bolster barzolvolimab’s potential to move CSU treatment toward disease modification and support continued Phase 3 evaluation. » Más en finance.yahoo.com
Datos financieros
En el último trimestre, Celldex Therapeutics tuvo unos ingresos de 0 € y un beneficio neto de -66,71 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | 100,00 % |
| Beneficio neto | -66,71 M | 16,76 % |
| EBITDA | -65,68 M | 16,40 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1962,78 M € |
Número de acciones | 78,55 M |
Máximo/mínimo de 52 semanas | 41,14 € - 20,35 € |
| Dividendos | No |
Beta | 0,90 |
Ratio P/E | -6,36 |
Ratio PEG | 0,26 |
Ratio P/B | 3,32 |
Ratio P/S | 19.229,51 |
Perfil de la empresa
Celldex Therapeutics, Inc., una empresa biofarmacéutica, se dedica al desarrollo de anticuerpos monoclonales y biespecíficos terapéuticos para el tratamiento de diversas enfermedades. Sus candidatos a fármacos incluyen terapias basadas en anticuerpos para tratar a pacientes con enfermedades inflamatorias y diversos tipos de cáncer. Los programas de desarrollo clínico de la compañía incluyen CDX-0159, un anticuerpo monoclonal en fase I que se une a la tirosina quinasa receptora KIT e inhibe su actividad; CDX-1140, un anticuerpo monoclonal agonista humano dirigido a CD40, un activador clave de la respuesta inmunitaria, que se encuentra en células dendríticas, macrófagos y linfocitos B, y que también se expresa en diversas células cancerosas; y CDX-527, un anticuerpo biespecífico que utiliza los anticuerpos humanos anti-PD-L1 y anti-CD27 activos y patentados de la compañía para acoplar la coestimulación de CD27 con el bloqueo de la vía PD-L1/PD-1, con el fin de ayudar a preparar y activar las respuestas de los linfocitos T antitumorales mediante la coestimulación de CD27. La compañía tiene acuerdos de colaboración en investigación y de licencia con la Universidad de Southampton para desarrollar anticuerpos humanos dirigidos a CD27; con Amgen Inc., que posee derechos exclusivos sobre CDX-301 y el ligando de CD40; y con la Universidad de Yale. Celldex Therapeutics, Inc. se constituyó en 1983 y tiene su sede en Hampton, Nueva Jersey.
| Nombre | Celldex Therapeutics |
| CEO | Anthony S. Marucci |
| Sede | Hampton,
nj Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Equipos y suministros sanitarios |
| Salida a bolsa | 15/05/1986 |
| Empleados | 198 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | CLDX |
Frankfurt | TCE2.F |
Düsseldorf | TCE2.DU |
SIX | TCE1.SW |
München | TCE2.MU |